The European Commission announced that it has accepted commitments proposed by pharmaceutical company Sanofi in connection with the review of an antitrust case. European Commission Executive Vice-President Teresa Ribeira, who oversees competition and industrial policy matters, made the announcement at a briefing in Brussels. In her opening remarks, Ribeira noted that the matter under consideration directly affects the interests of European Union citizens, emphasizing the importance of healthcare and the accessibility of medicines for Europeans. According to her, the European Commission continues systematic work to ensure fair competition in the pharmaceutical market. The decision to accept Sanofi's commitments is the result of an investigation conducted by the European Commission's antitrust authorities. Such commitments are typically adopted voluntarily by companies to address regulator concerns regarding possible violations of competition rules, which allows them to avoid formal acknowledgment of a violation and penalties provided the commitments are fulfilled. The European Commission regularly conducts inspections of major pharmaceutical companies for compliance with EU antitrust legislation, paying particular attention to pricing issues, access to innovative medicines, and possible practices that restrict competition in the generic drug market. This decision is viewed as part of the European Commission's broader strategy to protect consumer interests in the healthcare sector. Details of the specific commitments undertaken by Sanofi and their impact on the market and consumers are expected in subsequent official European Commission documents.